Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SinoMab BioScienceFRA:4VF 19 Current Ratio is 1.91 as of Dec. 2025, which is at its 10-year median of 1.91. GuruFocus rates FRA:4VF with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,408 Biotechnology companies, SinoMab BioScience ranks worse than 77.06% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. SinoMab BioScience's current ratio for the quarter that ended in Dec. 2025 was 1.91.
SinoMab BioScience has a current ratio of 1.91. It generally indicates good short-term financial strength.
The historical rank and industry rank for SinoMab BioScience's Current Ratio or its related term are showing as below:
FRA:4VF'
s Current Ratio Range Over the Past 10 Years
Min: 0.69 Med: 1.91 Max: 15.89
Current: 1.35
During the past 9 years, SinoMab BioScience's highest Current Ratio was 15.89. The lowest was 0.69. And the median was 1.91.
FRA:4VF's Current Ratio is ranked worse than 77.06% of 1408
companies
in the Biotechnology industry
Industry Median: 3.885
vs FRA:4VF: 1.35
SinoMab BioScience (FRA:4VF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
SinoMab BioScience Current Ratio Related Terms
SinoMab BioScience Current Ratio Historical Data
* Premium members only.
The historical data trend for SinoMab BioScience's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4VF vs VRTX, REGN, MRNA: Current Ratio Comparison
For the Biotechnology subindustry, SinoMab BioScience's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SinoMab BioScience Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SinoMab BioScience's Current Ratio distribution charts can be found below:
* The bar in red indicates where SinoMab BioScience's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SinoMab BioScience (FRA:4VF) has a Current Ratio of 1.91 as of Dec. 2025. This is near median its historical median of 1.91. Over the past decade, SinoMab BioScience's Current Ratio has ranged from 0.69 to 15.89. According to the industry distribution chart, SinoMab BioScience ranks #1085 out of 1408 companies in the Biotechnology industry, placing it in the top 77.1%.
Is SinoMab BioScience's Current Ratio too high?
SinoMab BioScience's current Current Ratio of 1.91 is near median its 10-year median of 1.91. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 15.89. The Biotechnology industry median Current Ratio is 3.89. SinoMab BioScience's value of 1.91 is 50.8% below this industry median. Based on the distribution chart, SinoMab BioScience ranks #1085 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SinoMab BioScience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SinoMab BioScience ranks #1085 out of 1408 companies for Current Ratio. This places SinoMab BioScience in the lower half of its industry. The industry median Current Ratio is 3.89. SinoMab BioScience's value of 1.91 is 50.8% below this benchmark. Historically, SinoMab BioScience's own Current Ratio has ranged from 0.69 to 15.89 over the past decade. While the company's 10-year median is 1.91 vs. the industry median of 3.89, SinoMab BioScience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SinoMab BioScience's current Current Ratio of 1.91 is 50.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SinoMab BioScience's current Current Ratio is 1.91, which is near median its own 10-year median of 1.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (FRA:4VF) has a current Current Ratio of 1.91. The current Current Ratio is 1.91, which is near median its 10-year median of 1.91 and 50.8% below the Biotechnology industry median of 3.89. SinoMab BioScience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For SinoMab BioScience (FRA:4VF), the current Current Ratio is 1.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
19GF Score
Get the complete analysis for FRA:4VF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4VF has been successfully added to your 
